Latest trial data. 440 randomized trial underway in Brazil, with control, high dose and low dose arms. They had to halt the high dose arm because of adverse effects (increased deaths) and no indication of enough efficacy to justify the AE.
https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v1
So far, I’ve seen properly randomized trials in which the drug has no significant efficacy advantage over control, observational/anecdotal reports w/o control arms where the drug was described as having efficacy but the clinical outcomes don’t look remarkable, and now this negative safety data.